Document is current

Article History

Received: 29 July 2024

Accepted: 5 March 2025

First Online: 20 March 2025

Declarations

:

: GEMINI tumor samples were analyzed under MD Anderson Cancer Center approved IRB protocol PA16-0061. IMpower133 (NCT02763579) is a randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study of atezolizumab (anti–PD-L1) in combination with CE (n = 201) compared with treatment with placebo in combination with CE (n = 202) in chemotherapy-naive participants with ES-SCLC. The study protocol (Horn et al., 2018) was approved by the institutional review board or independent ethics committee for each study site. All biological materials in this study were used in accordance with the informed consent agreements obtained from all subjects and all analyses were performed in full accordance with the Declaration of Helsinki.

: Not applicable.

: S.H. received speaker fees from Guardant health and AstraZeneca and reports intellectual property on the classification of lung cancer. E.A. has received speaking and/or advisory honoraria from Pfizer, Janssen, Sanofi, AstraZeneca, Bristol Myers Squibb, Lilly, Boehringer Ingelheim, Takeda, Roche, and MSD; and travel support from Takeda, Roche, and AstraZeneca. P.R. reports travel support from AstraZeneca, Merck Sharp & Dohme Corp., Bristol Myers Squibb, and Kiowa Kirin outside the submitted work. CMG reports research funding from AstraZeneca; consulting/advisory fees from Abdera Therapeutics, Amgen, AstraZeneca, Catalyst Pharmaceuticals, Daiichi Sankyo, G1 Therapeutics, Jazz Pharmaceuticals, Monte Rosa Therapeutics, Roche/Genentech, and STCube; speaking fees from Academy for Continued Healthcare Learning, Clinical Education Alliance, Dava Oncology, IDEOlogy, MJH Healthcare, PeerView, Physicians’ Education Resource; royalties from UpToDate, Inc.., and patent related to this work [U.S. Patent No. 11,732,306 issued on August 22, 2023 entitled “Molecular subtyping of small cell lung cancer to predict therapeutic responses”]. J.V.H. reports consulting fees from AbbVie, AnHeart Therapeutics, ArriVent Biopharma, AstraZeneca, BioCurity Pharmaceuticals, BioNTech AG, Blueprint Medicines, BI, BMS, Chugai Pharmaceutical, Curio Science, DAVA Oncology, Eli Lilly & Co, EMD Serono, Genentech, GSK, IDEOlogy Health, Immunocore, InterVenn Biosciences, Janssen Biotech, Janssen Pharmaceuticals, Mirati Therapeutics, Moffit Cancer Center, ModeX, Nexus Health Systems, Novartis Pharmaceuticals, OncoCyte, RefleXion, Regeneron Pharmaceuticals, Roche, Sandoz Pharmaceutical, Sanofi, Spectrum Pharmaceuticals, Takeda, and uniQure, honoraria from MJH Events, and Dr. Meil Love, as well as travel support from AACR. LAB reports research funding from AstraZeneca Pharmaceuticals, Amgen, and Circle Pharma; and consulting/advisory fees from Merck Sharp & Dohme Corp., Arrowhead Pharmaceuticals, Chugai Pharmaceutical Co., AstraZeneca Pharmaceuticals, Genentech Inc., BeiGene, AbbVie, Jazz Pharmaceuticals, Puma Biotechnology, Amgen, Daiichi Sankyo, and Novartis. M.C.L., B.Y.N., and D.S.S. are employees and stockholders of Genentech/Roche. B.B.M., Y.X., L.D., Q.W., D.R.T., K.R., C.A.S., R.J.C., R.W., V.Q., and J.W. report not conflicts of interest.